NASDAQ:LNTH Lantheus (LNTH) Stock Price, News & Analysis $92.89 -0.24 (-0.26%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$92.88 -0.02 (-0.02%) As of 05/19/2026 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lantheus Stock (NASDAQ:LNTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lantheus alerts:Sign Up Key Stats Today's Range$91.65▼$94.7250-Day Range$73.09▼$96.6752-Week Range$47.25▼$98.27Volume1.15 million shsAverage Volume971,519 shsMarket Capitalization$6.05 billionP/E Ratio22.38Dividend YieldN/APrice Target$99.71Consensus RatingModerate Buy Company Overview Lantheus Holdings, Inc. is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications. The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow. On the molecular imaging side, Lantheus markets Cardiolite® (technetium Tc-99m sestamibi) for myocardial perfusion imaging and Lexiscan® (regadenoson) for pharmacologic stress testing. In 2021, the company gained FDA approval and launched PYLARIFY® (piflufolastat F 18), a PET imaging agent for the detection of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. Lantheus also maintains a robust pipeline of next-generation PET and therapeutic candidates in collaboration with academic and industry partners. Founded in 1956, Lantheus has expanded its reach through strategic acquisitions and global partnerships, serving hospitals, imaging centers and research institutions in more than 50 countries. The company operates a network of manufacturing facilities across North America and Europe, adhering to stringent quality and regulatory standards. Lantheus’ leadership team comprises experienced executives from the pharmaceutical and medical imaging industries, guiding the organization’s growth in precision diagnostics and targeted radiopharmaceutical therapies. Continuous investment in research and development underpins Lantheus’ mission to deliver innovative solutions that improve patient outcomes and drive value for healthcare providers worldwide.AI Generated. May Contain Errors. Read More Lantheus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreLNTH MarketRank™: Lantheus scored higher than 52% of companies evaluated by MarketBeat, and ranked 525th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingModerate Buy Consensus RatingLantheus has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 8 buy ratings, 3 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Lantheus is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageLantheus has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Lantheus' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth25.35% Earnings GrowthEarnings for Lantheus are expected to grow by 25.35% in the coming year, from $4.30 to $5.39 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantheus is 22.38, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.39.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantheus is 22.38, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.79.Price to Book Value per Share RatioLantheus has a P/B Ratio of 4.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lantheus' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.86% of the float of Lantheus has been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 8.44.Change versus previous monthShort interest in Lantheus has recently increased by 11.08%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLantheus does not currently pay a dividend.Dividend GrowthLantheus does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.11 News SentimentLantheus has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Lantheus this week, compared to 12 articles on an average week.Search Interest5 people have searched for LNTH on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows4 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lantheus insiders have not sold or bought any company stock.Percentage Held by Insiders1.70% of the stock of Lantheus is held by insiders.Percentage Held by Institutions99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lantheus' insider trading history. Receive LNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LNTH Stock News HeadlinesLantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingMay 19 at 8:30 AM | globenewswire.comWe Think You Should Be Aware Of Some Concerning Factors In Lantheus Holdings' (NASDAQ:LNTH) EarningsMay 15, 2026 | finance.yahoo.comFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift. | Porter & Company (Ad)Lantheus Holdings (LNTH) price target increased by 10.39% to 103.33May 15, 2026 | msn.comLantheus Holdings, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 15, 2026 | seekingalpha.comBig Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category LeadersMay 14, 2026 | 247wallst.comLantheus' (LNTH) Buy Rating Reaffirmed at Truist FinancialMay 12, 2026 | americanbankingnews.comCitizens Jmp Raises Lantheus (NASDAQ:LNTH) Price Target to $115.00May 10, 2026 | americanbankingnews.comSee More Headlines LNTH Stock Analysis - Frequently Asked Questions How have LNTH shares performed this year? Lantheus' stock was trading at $66.55 on January 1st, 2026. Since then, LNTH shares have increased by 39.6% and is now trading at $92.89. How were Lantheus' earnings last quarter? Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its quarterly earnings data on Thursday, May, 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.25 by $0.21. The business's revenue was up 1.2% on a year-over-year basis. Read the conference call transcript. When did Lantheus IPO? Lantheus (LNTH) raised $103 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 10,833,334 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager. Who are Lantheus' major shareholders? Top institutional shareholders of Lantheus include Janus Henderson Group PLC (7.33%), Dimensional Fund Advisors LP (2.12%), Epoch Investment Partners Inc. (1.00%) and Healthcare of Ontario Pension Plan Trust Fund (0.92%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Farallon Partners L L C/Ca, Rajiv A Patel, Mary Anne Heino, Robert J Jr Marshall, Paul Blanchfield, Daniel Niedzwiecki, Andrea Sabens, James H Thrall, Heinz Christoph Maeusli, Gerard Ber, Gary J Pruden and Minnie Baylor-Henry. View institutional ownership trends. How do I buy shares of Lantheus? Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lantheus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lantheus investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings5/07/2026Today5/19/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 LNTH's financial health is in the Green zone, according to TradeSmith. LNTH has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LNTH CIK1521036 Webwww.lantheus.com Phone(978) 671-8001Fax978-671-8860Employees1,193Year FoundedN/APrice Target and Rating Average Price Target for Lantheus$99.71 High Price Target$115.00 Low Price Target$80.00 Potential Upside/Downside+7.3%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)$4.15 Trailing P/E Ratio22.38 Forward P/E Ratio21.60 P/E GrowthN/ANet Income$233.56 million Net Margins18.05% Pretax Margin24.17% Return on Equity29.32% Return on Assets15.00% Debt Debt-to-Equity Ratio0.47 Current Ratio2.83 Quick Ratio2.64 Sales & Book Value Annual Sales$1.54 billion Price / Sales3.92 Cash Flow$6.37 per share Price / Cash Flow14.59 Book Value$18.62 per share Price / Book4.99Miscellaneous Outstanding Shares65,110,000Free Float63,999,000Market Cap$6.05 billion OptionableOptionable Beta-0.08 Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:LNTH) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredHe doesn't buy gold. He just profits from it.Former hedge fund manager Larry Benedict generated $274 million in profits - and Barron's ranked his fund in t...Brownstone Research | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantheus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
